Drug Search Results
More Filters [+]

Triazolam

Alternative Names: triazolam, halcion
Latest Update: 2024-06-24
Latest Update Note: News Article

Product Description

Triazolam is a triazolobenzodiazepine with hypnotic properties, advocated for use in acute or chronic insomnia, situational insomnia in hospitalised patients, and insomnia associated with other disease states.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/6114852/)

Mechanisms of Action: GABA Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Canada | Chile | Colombia | Denmark | Dominican Republic | Finland | Germany | Greece | Hong Kong | Iceland | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | New Zealand | Pakistan | Peru | Portugal | Spain | Sweden | Switzerland | Taiwan | United States | Venezuela

Approved Indications: Insomnia

Known Adverse Events: Ataxia | Dizziness

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Triazolam

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events